MDV3100 for the treatment of prostate cancer

Author： Mukherji Deborah   Pezaro Carmel J   De-Bono Johann S  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.2, 2012-02, pp. : 227-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment

By Badrising Sushil   van der Noort Vincent   van Oort Inge M.   van den Berg H. Pieter   Los Maartje   Hamberg Paul   Coenen Jules L.   van den Eertwegh Alfons J. M.   de Jong Igle J.   Kerver Emile D.   van Tinteren Harm   Bergman Andries M.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

Blackwell Publishing

Access to resources Recommend Favorite

Cabazitaxel for the treatment of prostate cancer

By Michielsen Dirk PJ   Braeckman Johan G   Denis Louis  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 6, 2011-04 ,pp. : 977-982

Informa Healthcare

Access to resources Recommend Favorite

Hormonal treatment for prostate cancer

By Harris K.A.   Small E.J.  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 3, 2001-03 ,pp. : 493-510

Informa Healthcare

Access to resources Recommend Favorite

Targeting angiogenesis for the treatment of prostate cancer

By Antonarakis Emmanuel S   Carducci Michael A  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 4, 2012-04 ,pp. : 365-376

Informa Healthcare

Access to resources Recommend Favorite

An evaluation of bicalutamide in the treatment of prostate cancer

By Schellhammer Paul F  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 9, 2002-09 ,pp. : 1313-1328

Informa Healthcare

Access to resources Recommend Favorite